|
WO2021054867A1
|
|
IMMUNOCYTOKINE COMPRISING HETERODIMERIC PROTEIN COMPLEX BASED ON IL-15/IL-15Rα
|
|
RU2745814C1
|
|
Aqueous pharmaceutical composition of levilimab and the use thereof
|
|
CN111420049A
|
|
Aqueous pharmaceutical composition of anti-PD 1 antibody PRO L GO L IMAB and application thereof
|
|
TW202037365A
|
|
Aqueous pharmaceutical composition of an anti-il17a antibody and use thereof
|
|
WO2020027704A1
|
|
Cdk8/19 inhibitors
|
|
WO2019190359A1
|
|
Biospecific antibody that specifically binds to subdomains iv and ii of the extracellular domain of human her2
|
|
WO2019168446A1
|
|
Novel cdk 8/19 inhibitors
|
|
TW201922709A
|
|
Epidermal growth factor receptor inhibitors
|
|
TW201922781A
|
|
Antibodies specific to cd47 and pd-l1
|
|
TW201922789A
|
|
Monoclonal antibody to IL-5R[alpha]
|
|
RU2706298C1
|
|
PaCas9 NUCLEASE
|
|
EP3666770A1
|
|
Novel heterocyclic compounds as cdk8/19 inhibitors
|
|
WO2018151633A1
|
|
Methods for producing 4-(((naphthalen-2-yl)alkyl)amino)quinoxaline-6-carbonitrile derivatives
|
|
EP3563867A1
|
|
Aqueous pharmaceutical composition of a recombinant monoclonal antibody to tnf alfa
|
|
PE20191082A1
|
|
BRUTON TYROSINE KINASE INHIBITORS
|
